About Ralitsa Larsen

This author has not yet filled in any details.
So far Ralitsa Larsen has created 10 blog entries.

On-demand Webinar: Planning Successful Studies for Cell and Gene Therapy–What to Know Now

2021-01-13T21:43:38-05:00Cell & Gene Therapy, Events|

Join MassBio and Precision for a one-of-a-kind panel discussion with a unique group of experts in cell and gene therapy studies. These pioneers have been involved in multiple programs that led to FDA-approved cell and gene therapies. They will share lessons learned from experience, giving you actionable insights on every stage of a trial—from the lab, to studies, to logistics and biomanufacturing.


From Supplier to Public Health Player: The Changing Role of Biopharma Companies

2021-01-13T21:44:36-05:00Cell & Gene Therapy, Thought Leadership|

Access challenges to cell and gene therapy are well documented. Precision’s Christina Poschen and David Carr discuss how some innovative manufacturers are moving away from the role of being purely a researcher and manufacturer and toward involvement at the point of diagnosis through manufacturing and delivery to patient access support in order to address those challenges head on.


On-demand Webinar: Using HEOR Methods to Reduce Health Inequalities


Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.


On-demand Webinar: Gene Therapies In Hemophilia


As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.